A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy.
To study the preventive effect of itraconazole against fungal infections following chemotherapy in tumor patients, we conducted a double-blind randomized clinical trial in 114 tumor patients receiving chemotherapy, who were divided into itraconazole treatment group (n=52) and control group (n=62) and the incidences of fungal infections after chemotherapy were recorded. In comparison with the control group, itraconazole treatment group exhibited a significant decrease in fungal infection episodes (12.8% vs 3.8%), illustrating the efficacy of itraconazole treatment as a preventive measure against fungal infections secondary to chemotherapy.
Wang
Chun-Yan
CY
Department of Hematology, Zhujiang Hospital, First Military Medical University, Guangzhou 510282, China. yanchunwa@yahoo.com.cn
Wu
Bing-Yi
BY
Guo
Kun-Yuan
KY
D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004311:Double-Blind Method; D004358:Drug Therapy; D005260:Female; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use*; D008297:Male; D009181:Mycoses / Q000517:prevention & control*; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy; D009894:Opportunistic Infections / Q000517:prevention & control*; D016896:Treatment Outcome
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D017964:Itraconazole